We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

36 hedge funds and large institutions have $2.94M invested in Aspire Biopharma Warrant in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 36 → 36 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

60% less capital invested

Capital invested by funds: $7.27M → $2.94M (-$4.33M)

Holders
36
Holders Change
–
Holders Change %
0%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
6
Closed
5
Calls
$2.09M
Puts
–
Net Calls
+$2.09M
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$83K
2
MF
Magnetar Financial
Illinois
+$26K
3
CS
Clear Street
New York
+$19.4K
4
BCM
Basso Capital Management
Connecticut
+$7.34K
5
ACM
Atalaya Capital Management
New York
+$7.28K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$17K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$12K
3
WAM
Weiss Asset Management
Massachusetts
-$8K
4
PCM
Prelude Capital Management
New York
-$4K
5
UBS Group
UBS Group
Switzerland
-$3.64K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.66M +$2.01K +13,800 +9%
HCM
2
Highbridge Capital Management
New York
$151K – – –
SCM
3
Saba Capital Management
New York
$143K – – –
LA
4
Linden Advisors
New York
$131K – – –
PC
5
Periscope Capital
Ontario, Canada
$120K +$83K +570,000 +155%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$116K – – –
AA
7
AQR Arbitrage
Connecticut
$74K – – –
SC
8
Sculptor Capital
New York
$73K – – –
Verition Fund Management
9
Verition Fund Management
Connecticut
$48K -$1.16K -7,964 -2%
WAM
10
Wolverine Asset Management
Illinois
$44K -$630 -4,327 -1%
Barclays
11
Barclays
United Kingdom
$39K – – –
KC
12
Kepos Capital
New York
$39K – – –
TCA
13
Taconic Capital Advisors
New York
$36K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$34K – – –
Balyasny Asset Management
15
Balyasny Asset Management
Illinois
$29K – – –
MF
16
Magnetar Financial
Illinois
$29K +$26K +178,750 +883%
Nomura Holdings
17
Nomura Holdings
Japan
$20K – – –
CCM
18
Context Capital Management
California
$19K – – –
SRCM
19
Sage Rock Capital Management
New York
$18K -$3.43K -23,571 -13%
CS
20
Clear Street
New York
$16K +$19.4K +133,230 +964%
KL
21
KIM LLC
Kansas
$15K – – –
PAMP
22
Polar Asset Management Partners
Ontario, Canada
$15K – – –
WA
23
Whitebox Advisors
Minnesota
$14K – – –
PMAM
24
Picton Mahoney Asset Management
Ontario, Canada
$9K – – –
ACM
25
Atalaya Capital Management
New York
$9K +$7.28K +50,000 New
1
2

ASBPW Hedge Fund Activity: Q3 2022 in Review

36 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q3 2022, worth a combined $2.94M — down 60% from $7.27M a quarter earlier.

Fund positioning in ASBPW was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Periscope Capital, adding an estimated $83K. The largest seller was Woodline Partners, exiting entirely with an estimated $17K sold.

  • 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $2.94M of Aspire Biopharma Warrant stock for Q3 2022, down 60% quarter-over-quarter.
  • 5 funds opened new Aspire Biopharma Warrant positions in Q3 2022 and 5 closed out, a net change of 0 holders.
  • The largest Aspire Biopharma Warrant buyer in Q3 2022 was Periscope Capital, an estimated $83K added.
  • The largest Aspire Biopharma Warrant seller in Q3 2022 was Woodline Partners, an estimated $17K sold.

Based on aggregated 13F filings for Q3 2022.